Japanese Biotech JCR Pharmaceuticals Selects Medidata’s Cloud-Based Platform To Power Rare Disease Clinical Research In Japan

NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its cloud-based technology platform has been adopted by JCR Pharmaceuticals Co., Ltd. The Japanese pioneer in biotherapeutics is leveraging the Medidata Clinical Cloud® to support research on a therapy for the treatment of Fabry disease, bringing greater speed and operational efficiencies to the organization’s development program in Japan.

Help employers find you! Check out all the jobs and post your resume.